ES2921858T3 - Régimen de cladribina en el tratamiento de la esclerosis múltiple - Google Patents

Régimen de cladribina en el tratamiento de la esclerosis múltiple Download PDF

Info

Publication number
ES2921858T3
ES2921858T3 ES18151634T ES18151634T ES2921858T3 ES 2921858 T3 ES2921858 T3 ES 2921858T3 ES 18151634 T ES18151634 T ES 18151634T ES 18151634 T ES18151634 T ES 18151634T ES 2921858 T3 ES2921858 T3 ES 2921858T3
Authority
ES
Spain
Prior art keywords
cladribine
administered
period
months
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES18151634T
Other languages
English (en)
Spanish (es)
Inventor
Luca Giampiero De
Amaud Ythier
Alain Munafo
Maria Lopez-Bresnahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2921858(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono SA filed Critical Merck Serono SA
Application granted granted Critical
Publication of ES2921858T3 publication Critical patent/ES2921858T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES18151634T 2004-12-22 2005-12-20 Régimen de cladribina en el tratamiento de la esclerosis múltiple Expired - Lifetime ES2921858T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22

Publications (1)

Publication Number Publication Date
ES2921858T3 true ES2921858T3 (es) 2022-09-01

Family

ID=36227798

Family Applications (2)

Application Number Title Priority Date Filing Date
ES22166610T Expired - Lifetime ES3007339T3 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis
ES18151634T Expired - Lifetime ES2921858T3 (es) 2004-12-22 2005-12-20 Régimen de cladribina en el tratamiento de la esclerosis múltiple

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES22166610T Expired - Lifetime ES3007339T3 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Country Status (25)

Country Link
US (2) US7713947B2 (enExample)
EP (7) EP1827461B1 (enExample)
JP (7) JP5795456B2 (enExample)
KR (1) KR20070091662A (enExample)
AR (1) AR052830A1 (enExample)
AU (2) AU2005318190B2 (enExample)
BR (1) BRPI0517132B8 (enExample)
CA (2) CA3087419C (enExample)
CY (3) CY1112614T1 (enExample)
DK (3) DK4070800T3 (enExample)
EA (1) EA015799B1 (enExample)
ES (2) ES3007339T3 (enExample)
FI (1) FI4070800T3 (enExample)
FR (1) FR18C1008I2 (enExample)
HR (1) HRP20120228T1 (enExample)
HU (3) HUE059133T2 (enExample)
IL (2) IL183930A0 (enExample)
LT (3) LT4070800T (enExample)
LU (1) LUC00064I2 (enExample)
MX (1) MX2007007610A (enExample)
NO (1) NO20073813L (enExample)
PL (4) PL2805723T3 (enExample)
SG (1) SG160391A1 (enExample)
SI (3) SI4070800T1 (enExample)
WO (1) WO2006067141A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1827461B1 (en) 2004-12-22 2012-02-29 Merck Serono SA Cladribine regimen for treating multiple sclerosis
EP2026832B1 (en) * 2006-05-24 2012-05-02 Merck Serono SA Combination of interferon-beta and a cladribine regimen for treating multiple sclerosis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) * 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
AR113906A1 (es) * 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
ATE223221T1 (de) 1994-12-22 2002-09-15 Ortho Pharma Corp Lösliche arzneizusammensetzungen enthaltend 2- chloro-2'-deoxyadenosine
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
WO2004028462A2 (en) 2002-09-25 2004-04-08 Brigham Young University, Technology Transfer Office Method for the preparation of 2-halo-2'-deoxyadenosine compounds from 2'-deoxyguanosine
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
AU2004216485B2 (en) * 2003-02-25 2009-06-11 Merck Serono Sa Combined use of ribavirin and interferon beta in demyelinating diseases
MEP34508A (en) 2003-03-28 2011-02-10 Ares Trading Sa Cladribine formulations for improved oral and transmucosal delivery
PT1608344E (pt) * 2003-03-28 2010-09-02 Ares Trading Sa Formulações orais de cladribina
EP1827461B1 (en) 2004-12-22 2012-02-29 Merck Serono SA Cladribine regimen for treating multiple sclerosis
EP2026832B1 (en) * 2006-05-24 2012-05-02 Merck Serono SA Combination of interferon-beta and a cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
JP2015180685A (ja) 2015-10-15
JP2018165271A (ja) 2018-10-25
KR20070091662A (ko) 2007-09-11
LUC00064I1 (enExample) 2018-02-14
AU2005318190A1 (en) 2006-06-29
JP6290962B2 (ja) 2018-03-07
FI4070800T3 (fi) 2025-01-14
IL212421A0 (en) 2011-06-30
EP1827461A1 (en) 2007-09-05
CA2588966C (en) 2020-07-21
DK2805723T3 (da) 2018-01-29
JP2008524313A (ja) 2008-07-10
EP2275110A3 (en) 2011-04-27
JP2020193206A (ja) 2020-12-03
FR18C1008I1 (enExample) 2018-03-30
CY1119790T1 (el) 2018-06-27
HUS1800009I1 (hu) 2018-05-02
AU2011200768B2 (en) 2012-09-13
HUE059133T2 (hu) 2022-10-28
SI3332789T1 (sl) 2022-08-31
LUC00064I2 (enExample) 2018-03-28
EA015799B1 (ru) 2011-12-30
FR18C1008I2 (fr) 2019-03-01
EP4523753A3 (en) 2025-05-28
DK3332789T3 (da) 2022-07-11
DK4070800T3 (da) 2025-01-02
US8377903B2 (en) 2013-02-19
JP6092945B2 (ja) 2017-03-08
PL1827461T3 (pl) 2012-07-31
EP2275110A2 (en) 2011-01-19
SI4070800T1 (sl) 2025-03-31
PL4070800T3 (pl) 2025-03-10
LT3332789T (lt) 2022-07-25
SG160391A1 (en) 2010-04-29
ES3007339T3 (en) 2025-03-19
US20090081163A1 (en) 2009-03-26
BRPI0517132B8 (pt) 2021-05-25
BRPI0517132B1 (pt) 2020-02-18
LT4070800T (lt) 2025-01-10
MX2007007610A (es) 2007-08-03
CA2588966A1 (en) 2006-06-29
CA3087419A1 (en) 2006-06-29
CY2018006I2 (el) 2018-06-27
CY2018006I1 (el) 2018-06-27
JP2013216664A (ja) 2013-10-24
JP5908863B2 (ja) 2016-04-26
IL183930A0 (en) 2007-10-31
WO2006067141A1 (en) 2006-06-29
IL212421A (en) 2014-01-30
PL2805723T3 (pl) 2018-04-30
EP2805723B1 (en) 2018-01-17
EA200701221A1 (ru) 2008-02-28
CY1112614T1 (el) 2016-02-10
JP2016138128A (ja) 2016-08-04
EP2263678A2 (en) 2010-12-22
EP4070800B1 (en) 2024-10-16
BRPI0517132A (pt) 2008-09-30
EP2805723A1 (en) 2014-11-26
EP2263678B1 (en) 2014-06-11
HRP20120228T1 (hr) 2012-04-30
JP6430554B2 (ja) 2018-11-28
SI2805723T1 (en) 2018-02-28
LTPA2018503I1 (lt) 2018-03-12
CA3087419C (en) 2023-03-07
EP2263678A3 (en) 2011-04-27
JP5795456B2 (ja) 2015-10-14
NO20073813L (no) 2007-09-21
AU2011200768A1 (en) 2011-03-17
EP1827461B1 (en) 2012-02-29
LTC2805723I2 (lt) 2022-04-25
AR052830A1 (es) 2007-04-04
EP2275110B1 (en) 2013-07-10
US7713947B2 (en) 2010-05-11
PL3332789T3 (pl) 2022-08-22
EP4070800A1 (en) 2022-10-12
US20100203017A1 (en) 2010-08-12
EP4523753A2 (en) 2025-03-19
HUE070333T2 (hu) 2025-05-28
AU2005318190B2 (en) 2010-11-25
EP3332789A1 (en) 2018-06-13
JP2017101061A (ja) 2017-06-08
EP3332789B1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
US8377903B2 (en) Cladribine regimen for treating multiple sclerosis
ES2428741T3 (es) Pauta terapéutica de Cladribina para el tratamiento de esclerosis múltiple
HK40083827B (en) Cladribine regimen for treating multiple sclerosis
HK40083827A (en) Cladribine regimen for treating multiple sclerosis
CN101090726A (zh) 治疗多发性硬化的克拉屈滨方案